COV-flu
- Generic Name
- COV-flu
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
Phase 2
Active, not recruiting
- Conditions
- Mild to Moderate COVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Oneness Biotech Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT05941793
- Locations
- 🇨🇳
Taipei Municipal Wanfang Hospital, Taipei, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇺🇸Velocity Clinical Research, Salt Lake City, Utah, United States
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
Phase 1
Completed
- Conditions
- Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
- Interventions
- Other: Placebo
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Oneness Biotech Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT05677893
- Locations
- 🇺🇸
Phase I Unit, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath